Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production.

Tsutsumi K, Ohtsuka T, Mori Y, Fujino M, Yasui T, Aishima S, Takahata S, Nakamura M, Ito T, Tanaka M.

J Gastroenterol. 2012 Jun;47(6):678-85. doi: 10.1007/s00535-012-0540-0. Epub 2012 Feb 17.

PMID:
22350698
2.

Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.

Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK.

Pancreas. 2012 Aug;41(6):840-4. doi: 10.1097/MPA.0b013e31823cdaa0.

PMID:
22781907
3.

A personal experience with pancreatic and duodenal neuroendocrine tumors.

Jordan PH Jr.

J Am Coll Surg. 1999 Nov;189(5):470-82.

PMID:
10549736
4.

Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.

Boninsegna L, Panzuto F, Partelli S, Capelli P, Delle Fave G, Bettini R, Pederzoli P, Scarpa A, Falconi M.

Eur J Cancer. 2012 Jul;48(11):1608-15. doi: 10.1016/j.ejca.2011.10.030. Epub 2011 Nov 28.

PMID:
22129889
5.

Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors?

Fernández-Cruz L, Blanco L, Cosa R, Rendón H.

World J Surg. 2008 May;32(5):904-17. doi: 10.1007/s00268-008-9467-2.

PMID:
18264824
6.

Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution.

Dahdaleh FS, Calva-Cerqueira D, Carr JC, Liao J, Mezhir JJ, O'Dorisio TM, Howe JR.

Ann Surg Oncol. 2012 Mar;19(3):966-72. doi: 10.1245/s10434-011-1997-4. Epub 2011 Aug 16.

PMID:
21845496
7.

Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).

Hashim YM, Trinkaus KM, Linehan DC, Strasberg SS, Fields RC, Cao D, Hawkins WG.

Ann Surg. 2014 Feb;259(2):197-203. doi: 10.1097/SLA.0000000000000348.

8.

Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection.

Curran T, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N.

J Gastrointest Surg. 2015 Jan;19(1):152-60; discussion 160. doi: 10.1007/s11605-014-2624-z. Epub 2014 Aug 14.

PMID:
25118642
9.

Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.

Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT.

Arch Surg. 2003 Aug;138(8):859-66.

PMID:
12912744
10.

Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis.

Poultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Jeffrey RB, Park WG, Chen AM, Kunz PL, Fisher GA, Norton JA.

Ann Surg Oncol. 2012 Jul;19(7):2295-303. doi: 10.1245/s10434-012-2305-7. Epub 2012 Mar 7.

PMID:
22396008
11.

Determinants of surgical resection for pancreatic neuroendocrine tumors.

Doi R.

J Hepatobiliary Pancreat Sci. 2015 Aug;22(8):610-7. doi: 10.1002/jhbp.224. Epub 2015 Mar 13. Review.

PMID:
25773163
12.

Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors.

Cherenfant J, Stocker SJ, Gage MK, Du H, Thurow TA, Odeleye M, Schimpke SW, Kaul KL, Hall CR, Lamzabi I, Gattuso P, Winchester DJ, Marsh RW, Roggin KK, Bentrem DJ, Baker MS, Prinz RA, Talamonti MS.

Surgery. 2013 Oct;154(4):785-91; discussion 791-3. doi: 10.1016/j.surg.2013.07.004.

PMID:
24074416
13.

The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F.

J Gastrointest Surg. 2009 Jul;13(7):1337-44. doi: 10.1007/s11605-009-0919-2. Epub 2009 May 6.

PMID:
19418101
14.

Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?

Teh SH, Deveney C, Sheppard BC.

Am J Surg. 2007 May;193(5):610-3; discussion 613.

PMID:
17434366
15.

Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas.

Matthews BD, Heniford BT, Reardon PR, Brunicardi FC, Greene FL.

Am Surg. 2000 Dec;66(12):1116-22; discussion 1122-3.

PMID:
11149582
16.

ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.

Tachezy M, Zander H, Marx AH, Gebauer F, Rawnaq T, Kaifi JT, Sauter G, Izbicki JR, Bockhorn M.

J Surg Res. 2011 Oct;170(2):226-32. doi: 10.1016/j.jss.2011.06.002. Epub 2011 Jul 2.

PMID:
21816425
17.

Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience.

Ito H, Abramson M, Ito K, Swanson E, Cho N, Ruan DT, Swanson RS, Whang EE.

J Gastrointest Surg. 2010 May;14(5):891-8. doi: 10.1007/s11605-010-1173-3. Epub 2010 Mar 12.

PMID:
20224984
18.

Resection of pancreatic neuroendocrine tumors: results of 70 cases.

Kazanjian KK, Reber HA, Hines OJ.

Arch Surg. 2006 Aug;141(8):765-9; discussion 769-70.

PMID:
16924083
19.

Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy.

Fortner JG, Klimstra DS, Senie RT, Maclean BJ.

Ann Surg. 1996 Feb;223(2):147-53.

20.

Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience.

Wong J, Fulp WJ, Strosberg JR, Kvols LK, Centeno BA, Hodul PJ.

Am J Surg. 2014 Nov;208(5):775-80. doi: 10.1016/j.amjsurg.2014.04.003. Epub 2014 Jun 8.

PMID:
24997491

Supplemental Content

Support Center